http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Feb 2026 12:31:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./25997971.html si-local-file:///var/storage/secattach/20260213/25997971.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./25997971.html Fri, 13 Feb 2026 12:31:00 -0500 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./25997971.html si-local-file:///var/storage/secattach/20260213/25997971.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./25997971.html Fri, 13 Feb 2026 12:31:00 -0500 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+SymBiosis+Capital+Partners%2C+LLC/25990623.html si-local-file:///var/storage/secattach/20260212/25990623.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+SymBiosis+Capital+Partners%2C+LLC/25990623.html Thu, 12 Feb 2026 13:45:00 -0500 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+SymBiosis+Capital+Partners%2C+LLC/25990623.html si-local-file:///var/storage/secattach/20260212/25990623.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+SymBiosis+Capital+Partners%2C+LLC/25990623.html Thu, 12 Feb 2026 13:45:00 -0500 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922803.html si-local-file:///var/storage/secattach/20260130/25922803.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922803.html Fri, 30 Jan 2026 14:44:00 -0500 O.52433366 RANI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922803.html si-local-file:///var/storage/secattach/20260130/25922803.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rani+Therapeutics+Holdin+++++++++++++++Filed+by%3A+VANGUARD+GROUP+INC/25922803.html Fri, 30 Jan 2026 14:44:00 -0500 O.52433366 RANI http://www.streetinsider.com/Corporate+News/Rani+Therapeutics+promotes+Alireza+Javadi+to+chief+technical+officer/25903824.html <p>Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. The clinical-stage biotherapeutics company focuses on oral delivery of biologics and drugs.</p><p>Javadi previously served as Vice President, Technical Operations, overseeing the company's research and development, manufacturing, and automation teams. In his expanded role, he will continue leading these functions while adding quality assurance responsibilities.</p><p>"His technical and operational leadership experience in the medical device and life science industries will be instrumental in scaling our supply chain and manufacturing capabilities as we continue to advance our pipeline," said Talat Imran, Chief Executive Officer of Rani http://www.streetinsider.com/Corporate+News/Rani+Therapeutics+promotes+Alireza+Javadi+to+chief+technical+officer/25903824.html Wed, 28 Jan 2026 07:01:54 -0500 RANI http://www.streetinsider.com/Management+Changes/Rani+Therapeutics+promotes+Alireza+Javadi+to+chief+technical+officer/25903824.html <p>Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. The clinical-stage biotherapeutics company focuses on oral delivery of biologics and drugs.</p><p>Javadi previously served as Vice President, Technical Operations, overseeing the company's research and development, manufacturing, and automation teams. In his expanded role, he will continue leading these functions while adding quality assurance responsibilities.</p><p>"His technical and operational leadership experience in the medical device and life science industries will be instrumental in scaling our supply chain and manufacturing capabilities as we continue to advance our pipeline," said Talat Imran, Chief Executive Officer of Rani http://www.streetinsider.com/Management+Changes/Rani+Therapeutics+promotes+Alireza+Javadi+to+chief+technical+officer/25903824.html Wed, 28 Jan 2026 07:01:54 -0500 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Press+Releases/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html <p align="justify">SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.</p> <p align="justify">“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and http://www.streetinsider.com/Globe+Newswire/Rani+Therapeutics+Announces+the+Promotion+of+Alireza+Javadi%2C+Ph.D.+to+Chief+Technical+Officer/25903793.html Wed, 28 Jan 2026 07:00:00 -0500 A.16632791 A.42843425 A.60003552 A.60004869 O.00003797 O.11570363 O.16363956 O.52433366 O.58228551 RANI